

Consensus based framework for digital mobility monitoring

Felix Kluge^{1,*}, Silvia Del Din², Andrea Cereatti³, Heiko Gaßner⁴, Clint Hansen⁵, Jorunn L Helbostadt⁶, Jochen Klucken⁴, Arne Küderle¹, Arne Müller⁷, Lynn Rochester^{2,8}, Martin Ullrich¹, Bjoern M Eskofier¹, Claudia Mazzà⁹, and on behalf of the Mobilise-D consortium¹⁰

¹Machine Learning and Data Analytics Lab, Department Artificial Intelligence in Biomedical Engineering, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

²Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

³Department of Electronics and Telecommunications, Politecnico di Torino, Torino, Italy

⁴Department of Molecular Neurology, University Hospital Erlangen, Erlangen, Germany

⁵Department of Neurology, University of Kiel, Kiel, Germany

⁶Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

⁷Novartis Pharma AG, Basel, Switzerland

⁸The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK

⁹Department of Mechanical Engineering & Insigneo Institute for in silico Medicine, The University of Sheffield, Sheffield, UK

¹⁰Full membership of the Mobilise-D consortium is available on the website <https://www.mobilise-d.eu>

*felix.kluge@fau.de

ABSTRACT

Digital mobility assessment using wearable sensor systems has the potential to capture walking performance in a patient's natural environment. It enables the monitoring of health status and disease progression and outcome evaluation of interventions in real-world situations. In contrast to laboratory settings, real-world walking occurs in non-conventional environments and under unconstrained and uncontrolled conditions. Despite the general understanding, there is a lack of agreed definitions about what constitutes real-world walking, impeding the comparison and interpretation of the acquired data across systems and studies. Hence, there is a need for a terminological framework for the guidance of further algorithmic implementation of digital measures for gait assessment. We used an objective methodology based on an adapted Delphi process to obtain consensus on specific terminology related to real-world walking by asking a diverse panel of clinical, scientific, and industrial stakeholders. Six constituents ('real-world', 'walking', 'purposeful', 'walking bout', 'walking speed', 'turning') have successfully been defined in two feedback rounds. The identification of a consented set of real-world walking definitions has important implications for the development of assessment and analysis protocols, as well as for the reporting and comparison of digital mobility outcomes across studies and systems. The definitions will serve as a common framework for implementing digital and mobile technologies for gait assessment.

1 Introduction

2 Mobility in general, and gait in particular, can be affected by a variety of chronic health conditions,
3 spanning from neurological, such as in multiple sclerosis (MS) and Parkinson’s disease (PD), to respiratory,
4 such as in chronic obstructive pulmonary disease (COPD), cardiac like in congestive heart failure (CHF),
5 or musculoskeletal disorders such as in proximal femoral fracture (PFF) recovery¹⁻⁶. Such functional
6 mobility impairments present a great burden to patients, as they are associated with severe limitations in
7 quality of life⁷⁻⁹, increased fall risk¹⁰⁻¹², and mortality^{13,14}.

8 Changes in various gait measures such as cadence, gait speed, stride length amongst others may
9 characterize those mobility impairments. The use of digital mobility outcomes (DMOs), which we refer to
10 as digital measures acquired using digital health technology¹⁵ has already been studied in clinical settings
11 using brief standardized tests in a range of diseases^{2,4,16,17}. However, a single observation may not be
12 reliable for clinical characterization especially when mobility related disease symptoms fluctuate over time,
13 sometimes even on an hourly basis. Therefore, the objective assessment of gait calls for valid and reliable
14 methods to sensitively capture changes in gait function more frequently¹⁸. As it is not feasible to increase
15 patient visits to the clinic, a more continuous monitoring outside laboratory or clinical environments
16 is desired¹⁹. Thus, the continuous assessment of real-world digital measures is essential and opens the
17 opportunity for frequent and long-term remote monitoring^{18,20-22}. In the past years, real-world gait
18 analysis has been technologically enabled by the development of lightweight and easy to use sensor-based
19 systems that can be worn unobtrusively. Although DMOs quantified from real-world data are able to
20 discriminate and detect gait impairments in various diseases^{20,23-26}, accepted and routinely used tools are
21 not applied in practice yet²⁷.

22 Whilst real-world measurement of mobility holds promise, one fundamental reason for the missing
23 adoption is the difficulty of comparing DMOs across studies due to the inconsistent use of terminology.
24 As an example, a broad variety of terms describing the “real-world“ context exist, including “real-life”,
25 “daily-life”, “everyday-life”, and “free-living”^{19,20,28,29}, that are used interchangeably with ambiguous
26 definitions. This can lead to different test paradigms being considered impeding comparability across
27 measurements, systems, and studies. Furthermore, observed DMO variations may not only be caused by
28 disease symptoms but also environmental factors and measurement protocols, which affect the reliability
29 of DMO assessment. Therefore, unified definitions of relevant DMOs and the context of measurement
30 are necessary to guarantee clinical meaningfulness. As a further example, the term “walking bout” has
31 been used in the context of real-world gait analysis and refers to the quantification of continuous periods
32 of free-living walking³⁰. However, walking bout definitions are inconsistent and may include different
33 walking bout durations and number of strides^{10,12,28,30-32}. The duration of resting periods between
34 walking bouts³³, and whether turning is considered as part of walking^{34,35} are treated differently as well.
35 However, a clear definition of a “walking bout” is critical, since it directly affects digital measures^{28,36}.
36 Additionally, "turning" needs to be considered as a main constituent of walking, as an average of more

37 than 60 turns per hour has been reported for real-world walking³⁴. Due to their high occurrence, turnings
38 are likely to break sequences of straight walking into smaller walking bouts. Therefore, the specific
39 definition of a turn directly influences the distribution of walking bouts with regard to their duration.
40 Furthermore, spatio-temporal parameters during straight walking and turning differ³⁷, such that real-world
41 DMOs based on averages of those parameters strongly depend on whether turning is included in their
42 estimation. Currently, different operational approaches exist for the detection of turning. As an example,
43 turning characteristics may be based on stride to stride angular parameters using foot rotation³⁸ or on
44 angular changes related to the trunk rotation³⁴. This diversity highlights the need for defining "turning"
45 in a framework of DMO assessment, which will enable a more specific operationalization of real-world
46 DMOs.

47 Overall, a guiding framework for the implementation of DMOs in real-world settings is still miss-
48 ing. Accordingly, the aim of this study was building a terminological framework in order to drive the
49 development and assessment of DMOs for real-world monitoring. We aimed to reach agreement upon a
50 set of narrative definitions within the scope of the Mobilise-D project¹⁵, which is a five-year EU-funded
51 IMI consortium that will build a technically and clinically-valid system for real-world digital mobility
52 assessment across multiple populations with the goal to improve healthcare. We used an objective and
53 systematic consensus process based on an adapted Delphi method³⁹. Our results will enable operational
54 definitions to implement mobility assessment algorithms, foster comparability across studies, and serve as
55 a common communication framework for the scientific community. Perspective, consensus on such a
56 terminological framework is a prerequisite for the adoption of validated digital biomarkers characterizing
57 mobility impairments in various diseases^{15,27}.

58 Results

59 Our approach of defining a terminological framework consisted of the following steps. First, relevant
60 domains and key terms related to real-world walking for the consensus process were identified. Six terms
61 related to four domains of real-world walking needing group consensus were selected (Table 1). For
62 some terms, different aspects were regarded. For example, we proposed a physiological definition of
63 "walking" and highlighted its relationship to walking bouts. For the definition of "real-world", we defined
64 fundamental characteristics, how it is discriminated from standardized measurements and which test
65 paradigms in the clinical context may be regarded as real-world assessment. "Walking speed" has been
66 physically defined. Additionally, we defined the need to consider different granularities when calculating
67 aggregated speed measures and proposed that real-world walking speed needs to be inherently connected
68 to walking bouts. We proposed initial definitions for those eleven aspects based on the study team's
69 expert knowledge and the current state of literature. Iterative feedback was included to improve structure
70 and content of the definitions (for the initial definitions refer to Supplementary Table 1). We used these
71 definitions as starting point for the subsequent consensus process.

72 **Consensus process**

73 We chose an adapted Delphi process to reach agreement on the initial definitions. A detailed description
74 of the experimental protocol and the data analysis can be found in the *Methods* section. In short, a Delphi
75 process is an objective iterative and anonymous process of asking participants for feedback on proposed
76 statements and adjusting those statements until overall consensus is reached³⁹. We defined that more
77 than 75 % agreement to a statement was required to reach consensus, which is in line with previous
78 literature^{49,52}.

79 In total, the consensus process required two rounds until agreement on all definitions was reached.
80 162 members of the Mobilise-D consortium were asked to participate in the first round of the consensus
81 process. Of those, 79 individuals started the questionnaire. Eight individuals did not sign the participation
82 or data usage agreement and five participants did not complete the questionnaire. Hence, their data was
83 discarded. Data from the remaining 66 participants (40.7 % response rate in the first round) were analysed.
84 Of the participants who completed the first round, 55 individuals started the second round. One individual
85 did not sign the participation agreement and three individuals did not complete the questionnaire. We
86 analysed the data of the remaining 51 participants (continuation response rate of 77.3 %). The overall
87 response rate regarding both rounds was 31.5 %. The professional background of the panel was diverse
88 but homogeneously distributed across clinical and technical disciplines (Table 2). Only 12.1 % stated to
89 have no experience in gait analysis. Two thirds of all individuals had expertise in free-living mobility.
90 Most participants (88.7 %) stated to have expertise with patients in the past. As answering the background
91 questions was not obligatory, the total number differs from the total number of individuals who participated
92 in round one of the process.

93 **Agreement on definitions**

94 In round one, the definitions of "Purposeful" and "Walking speed (Relation to walking bouts)" did not
95 reach agreement (Table 3) and were subject to modification based on participants' feedback. Although the
96 definition of "Walking bout" reached agreement, there was in clarity regarding its inherent connection to
97 the "Walking speed" definition. "Walking speed" initially assumed a different number of strides required
98 to assess average walking speed (for the initial definitions refer to the Supplementary Table 1). Therefore,
99 we decided to harmonize the "Walking bout" and "Walking speed (Relation to walking bouts)" definitions,
100 which were both put to vote again in the second round. Full consensus for all definitions was reached in
101 round two (Table 3) resulting in a final set of definitions for real-world gait analysis (Table 4).

102 **Discussion**

103 To the best of the authors' knowledge, this has been the first study to engage clinicians, academic re-
104 searchers, and industry stakeholders working in the field of digital gait and mobility measures development
105 to identify and agree upon a framework of narrative definitions for the assessment of DMOs acquired
106 in real-world conditions. An adapted Delphi consensus process allowed to achieve consensus on eleven

107 statements related to six key terms of real-world walking.

108 A broad definition of walking may include various displacements of the body in space (e.g. for-, back-,
109 or side-ward walking). We, however, define walking to be only associated with forward displacement
110 using both legs in order to assure reliability of DMO assessment in various contexts. Stepping on the
111 spot, side stepping, and backward walking have thus been excluded from this definition. Walking is also
112 not defined in terms of a specific speed. The use of walking aids has been included into the definition as
113 they may be an essential requirement for safe locomotion of people with gait impairments. Otherwise,
114 certain patients and elderly individuals might be excluded from the DMO assessment. We acknowledged
115 steps and strides as basic elements of walking as previously suggested⁴⁵. Furthermore, the definitions
116 include that walking is always made up of walking bouts. It was agreed that walking bouts represent
117 sequences containing at least two full consecutive strides of both feet without a break (e.g. *R-L-R-L-R-L*
118 or *L-R-L-R-L-R*, with *R/L* being the contacts of the right/left foot with the ground, respectively). Start and
119 end of a walking bout are determined by a break that can either consist of a resting period, turning, or any
120 other non-walking real-world activity. More specifically, the start is always defined by an initial step of a
121 walking bout following a non-walking period, while the final step precedes the next non-walking period.
122 Walking bouts are thus an important building block in the terminology framework for the assessment of
123 DMOs acquired in real-world conditions.

124 Walking speed has been referred to as “the sixth vital sign”, as slow walking has been associated with
125 morbidity, cognitive decline, and fall risk amongst others^{13,46}. Despite this, there is still no accepted
126 common measure of mobility that serves across multiple conditions, which is underlined by a wide range
127 of inconsistent testing procedures. With an operative definition of walking speed and a proposition of
128 respective aggregation levels at which it is measured, we aim to provide a common framework to be used
129 across clinical conditions. The physical definition of the walking speed definition reached high consensus.
130 The panel agreed that walking speed will be assessed based on a minimal number of consecutive strides.
131 According to clinical questions, walking speed needs to be assessed with regard to different aggregation
132 levels (hourly, daily, weekly, etc.). This definition is in line with the walking bout definition. On the
133 one hand, this specification yields a unified approach of assessing speed in our framework, but requires
134 a stride-wise analysis of walking, which might not be feasible in all analysis cases, for example when
135 the extraction of single strides is not feasible. The definition also suggests that walking speed derived
136 from strides that are not part of walking bouts (i.e. short strides, shuffling, turning, etc.) should not be
137 considered for the estimation of real-world walking speed.

138 Daily mobility does not only contain straight walking but also curved walking and turns. Therefore,
139 we included a definition of turning in the framework to guide the implementation of walking bouts and
140 the related DMO assessment. Turning can be regarded as being a deceleration of the forward motion,
141 rotating the body as a whole, and stepping out toward the new direction⁴⁴. It results in a change of
142 walking direction and change in angular orientation including a rotational movement of the body around
143 the longitudinal axis. As an example, a threshold on the rotation angle (e.g. $> 45^\circ$) at a certain turn

144 duration (e.g. between 0.5 s and 10 s) can be used to detect a turn³⁴. This definition does not include all
145 the required aspects for quantitative ambulatory mobility measurement. For example, further discussion
146 will be necessary to define specific angular thresholds between straight and non-straight (i.e. curvilinear)
147 walking. However, those operational definitions are not part of the narrative framework considered in
148 this study and are, therefore, part of future evaluations based on real-world data from different clinical
149 populations.

150 The environmental context of walking greatly influences DMOs. Thus, it was deemed necessary to
151 specify inclusion and exclusion criteria of what is considered real-world. The participants agreed on
152 different aspects of the terminology: real-world is conceptualized as free-living, unsupervised, uncontrolled
153 and non-standardized. In the real-world context, the measurement of DMOs should not interfere with
154 daily activities of the participant. The measurement process of real-world DMOs should thus be as
155 non-obtrusive as possible. Accordingly, this definition is distinct from laboratory-based⁴³, supervised
156 (fully controlled and observed), and semi-controlled (walking freely but with supervision) environments,
157 in which observer and instruction effects might occur and influence DMOs. For example, walking happens
158 in non-simulated real-world situations in unconstrained environments equivalent to actions at home or in
159 the community over continuous periods of time²⁸. Daily-living, including home and clinical environment
160 are equivalent to real-world as long as the walking happens unsupervised. Scripted walking capacity tests
161 such as 4x10 m walking conducted at home are excluded from the definition, as significant differences
162 between DMOs derived from those tests and DMOs acquired during unscripted real-world walking are
163 expected⁴⁷. However, differences and relationships between standardized tests and real-world assessments
164 still need to be evaluated in future research studies.

165 The participants agreed to the definition of purposeful as a consistent term for the assessment of
166 DMOs acquired in real-world conditions. Purposeful walking includes an intentional component of the
167 movement. We assume that unsupervised walking is per se purposeful and that the intentional aspect
168 occurs especially for long walking bouts and needs to be evaluated taking for example contextual aspects
169 of walking into account. Differences between purposeful, self-initiated movements, and movements
170 performed in a supervised (and thus not real-world setting) are discussed in detail in⁴⁸, and should be
171 further investigated with the consented real-world walking definitions.

172 The definitions agreed upon in this study are suggestions in order to capture gait analysis characteristics
173 and properties in the real-world environment. The goal to have working definitions for various clinical
174 populations has, on the one hand, resulted in a rather broad definition of walking (i.e. inclusion of
175 walking aids). On the other hand, clarity on specific parts of the definition (i.e. that walking only includes
176 forward locomotion) will allow to implement very specific digital mobility measures without restricting
177 the application cases.

178 While the Delphi approach is commonly used to obtain broad consensus among experts by determining
179 the level of agreement on a given topic³⁹ there is always a certain bias. We used purposive sampling under
180 the assumption that members of the Mobilise-D consortium represented experts in the field of real-world

181 gait research. In general, we acknowledge that the choice of participants restricted to the consortium limits
182 generalizability of the results. However, the consortium includes a large group of experts on gait analysis
183 from Europe and the USA. The participants were homogeneously distributed regarding technical and
184 clinical background. Their views were gathered from a wide range of clinical and academic disciplines
185 to equally represent a breadth of expertise. Some participants stated no experience with gait analysis
186 before. However, most of the participants explicitly mentioned having worked in the field of free-living
187 gait analysis. Moreover, the larger proportion of the participants already had experience in clinical gait
188 analysis. Nevertheless, further work is needed to validate the results of our study in light of an even
189 broader international group of gait experts. For example, the survey could be opened to a wider panel
190 to validate and refine the findings. Furthermore, the framework needs to be evaluated with regard to
191 clinical interpretability of the acquired DMOs based on actual real-world data. Overall, given geographical
192 spread, the Delphi consensus method conducted online was an appropriate tool for gathering the different
193 viewpoints as compared to physical discussion rounds.

194 The low response rates observed in this study, especially in the first round, are typical for consensus
195 processes and have previously been reported⁴⁹. Especially with large sample sizes, low response rates
196 are considered to be a drawback⁵⁰. Specifically to this study, we invited all members of the Mobilise-D
197 consortium to take part in the study, if they could comment on the topic. Some of the participants invited
198 might not have had a real-world gait analysis background or interest and did therefore not participate
199 in the process. As discussed, the analysis of the participants' professional background showed that the
200 included participants had relevant experience in the field of interest. Furthermore, the final sample size of
201 51 participants was higher than the lower threshold of 12, which has been regarded as minimal number to
202 ensure reliability of results in a consensus process⁵¹.

203 Only group feedback in the questionnaires were provided, as individual feedback was not possible due
204 to anonymity. However, the participants were sent an email with their individual responses and comments
205 after completion of a round. This allowed them to reflect on their own ratings in the subsequent round.

206 One limitation of this study is that the definitions are only of narrative nature. While the obtained
207 definitions have been objectively derived, some may need refinement according to the practical needs to
208 directly guide algorithm implementation (e.g. thresholds on differentiating turning from curvilinear or
209 straight walking need to be derived from further consensus or based on real-world data). Whilst extracting
210 and analysing DMOs, more detailed definitions need to be derived from the initial framework to enlarge the
211 scope and ensure applicability across different technologies and solutions for real-world gait assessment.

212 This work was conducted as part of the Mobilise-D project¹⁵ with the aim to guide the data analysis
213 process regarding real-world walking analysis with a focus on the assessment of real-world walking speed.
214 It has to be noted, that different ways of assessing real-world mobility exist, such as analyzing daily
215 activity patterns (e.g. daily step count, physical activity, energy expenditure amongst others). Related
216 digital measures are of high interest for some diseases and might benefit from similar terminological
217 frameworks.

218 In conclusion, consensus on narrative definitions for the assessment of gait related DMOs acquired
219 in real-world conditions was obtained through an objective consensus process, which has important
220 consequences for clinical gait and mobility research, and the implementation of digital measures. Future
221 work within the community may evaluate DMOs based on those definitions, which will improve compa-
222 rability between studies and settings. The results of this study have thus important implications for the
223 development of standardized analyzig protocols, as well as for the reporting, and comparison of DMOs.
224 Overall, the definitions will allow a standardized and more precise use of those terms in future studies,
225 enabling a stronger congruence of clinical, technical, and regulatory activities in this field.

226 **Methods**

227 We adopted an objective consensus building process for the study based on the Delphi methodology³⁹. In
228 contrast to quantitative methods such as systematic reviews or meta-analyses, which are based on available
229 literature and studies, the Delphi process allows to obtain consensus among experts by determining the
230 level of agreement on a given topic³⁹. Specifically, the Delphi method is characterized by anonymity
231 to avoid dominance of single experts, multiple iterations, and feedback to the group. As such, a basic
232 Delphi technique can contain any type of self-administered questionnaire with no meetings⁵², which is
233 the approach that was used in this explorative study to quantitatively assess the agreement on the initial
234 definitions.

235 A consensus process may consist of multiple rounds until agreement on the definitions is reached.
236 Based on a 5-point Likert scale (Figure 1), agreement was quantitatively assessed amongst the partici-
237 pants⁴⁹. A neutral statement (“No opinion”) was included. In our study, agreement to a given definition
238 was defined a-priori^{52,53} as more than 75 % of the answers belonging to the categories "Somewhat agree"
239 or "Strongly agree". In the first round, the participants were asked to independently rate all eleven state-
240 ments across the six key terms “Walking”, “Purposeful”, “Real-world”, “Walking bout”, “Walking speed”.
241 Additionally, participants were asked to provide free-text comments for each item in order to capture
242 input for the improvement of definitions⁴⁹. In subsequent rounds, we presented modified definitions that
243 previously did not reach agreement and assessed the agreement.

244 The consensus process was performed among member of the Mobilise-D consortium. The project
245 includes technical, clinical, and regulatory expertise of 34 partners from Europe and the USA. All 162
246 members of the consortium were asked for participation via email. Participants who did not respond in the
247 first round were not invited to participate in the second round. We did not define any exclusion criteria.
248 Data on participants’ “technical or clinical background”, “gait expertise”, “free-living expertise”, and
249 “expertise with patients” were collected in the first round to analyse the panel’s background.

250 The consensus process was implemented as a series of questionnaires based on the “Survey” feature
251 of the ILIAS E-learning platform (version 5.4.5, ILIAS open source e-Learning e. V.). It allowed the
252 anonymous acquisition of responses. The participants’ email addresses were linked to access codes,
253 which were provided to start the questionnaire. The use of access codes allowed sending reminders

254 to the participants and preventing double participation. The acquisition and analysis of the data was
255 anonymous. Descriptive statistics was used to investigate participants' background information and
256 agreement responses in each round. Analyses were conducted using R version 4.0.3⁵⁴.

257 Ethical approval for this study was granted by the ethics committee of the University Hospital Erlangen
258 (Re.-No. 241_19 Bc). All participants provided informed consent for inclusion in the study. Participation
259 in this study was voluntary. All data were handled in accordance with European data protection regulations.

260 References

- 261 1. Magaziner, J. *et al.* Recovery From Hip Fracture in Eight Areas of Function. *The Journals Gerontol.*
262 *Ser. A: Biol. Sci. Med. Sci.* **55**, M498–M507 (2000), <https://doi.org/10.1093/gerona/55.9.M498>.
- 263 2. Schlachetzki, J. C. M. *et al.* Wearable sensors objectively measure gait parameters in Parkinson's
264 disease. *PLOS ONE* **12**, e0183989 (2017), <https://doi.org/10.1371/journal.pone.0183989>.
- 265 3. Karpman, C. & Benzo, R. Gait speed as a measure of functional status in COPD patients. *Int. J.*
266 *Chronic Obstr. Pulm. Dis.* **9**, 1315 (2014), <https://doi.org/10.2147/COPD.S54481>.
- 267 4. Spain, R. I. *et al.* Body-worn motion sensors detect balance and gait deficits in people with multiple
268 sclerosis who have normal walking speed. *Gait & Posture* **35**, 573–578 (2012), <https://doi.org/10.1016/j.gaitpost.2011.11.026>.
- 269 5. Martin, C. L. *et al.* Gait and balance impairment in early multiple sclerosis in the absence of clinical
270 disability. *Multiple Scler.* **12**, 620–628 (2006), <https://doi.org/10.1177/1352458506070658>.
- 271 6. van den Berg-Emons, H. R., Bussmann, J. H., Balk, A., Keijzer-Oster, D. & Stam, H. Level of
272 Activities Associated With Mobility During Everyday Life in Patients With Chronic Congestive
273 Heart Failure as Measured With an Activity Monitor. *Phys. Ther.* **81**, 1502–1511 (2001), <https://doi.org/10.1093/ptj/81.9.1502>.
- 274 7. Kohn, C. G., Baker, W. L., Sidovar, M. F. & Coleman, C. I. Walking Speed and Health-Related
275 Quality of Life in Multiple Sclerosis. *The Patient - Patient-Centered Outcomes Res.* **7**, 55–61 (2014),
276 <https://doi.org/10.1007/s40271-013-0028-x>.
- 277 8. Gimeno-Santos, E. *et al.* Determinants and outcomes of physical activity in patients with COPD: a
278 systematic review. *Thorax* **69**, 731–739 (2014), <https://doi.org/10.1136/thoraxjnl-2013-204763>.
- 279 9. Schmid, A. *et al.* Improvements in Speed-Based Gait Classifications Are Meaningful. *Stroke* **38**,
280 2096–2100 (2007), <https://doi.org/10.1161/STROKEAHA.106.475921>.
- 281 10. Brodie, M. A., Lord, S. R., Coppens, M. J., Annegarn, J. & Delbaere, K. Eight-Week Remote
282 Monitoring Using a Freely Worn Device Reveals Unstable Gait Patterns in Older Fallers. *IEEE*
283 *Transactions on Biomed. Eng.* **62**, 2588–2594 (2015), <https://doi.org/10.1109/TBME.2015.2433935>.
- 284
- 285

- 286 **11.** Brodie, M. A. *et al.* Comparison between clinical gait and daily-life gait assessments of fall risk in
287 older people. *Geriatr. & Gerontol. Int.* **17**, 2274–2282 (2017), <https://doi.org/10.1111/ggi.12979>.
- 288 **12.** Weiss, A. *et al.* Does the Evaluation of Gait Quality During Daily Life Provide Insight Into Fall Risk?
289 A Novel Approach Using 3-Day Accelerometer Recordings. *Neurorehabilitation Neural Repair* **27**,
290 742–752 (2013), <https://doi.org/10.1177/1545968313491004>.
- 291 **13.** Studenski, S. Gait Speed and Survival in Older Adults. *JAMA* **305**, 50 (2011), [https://doi.org/10.1001/](https://doi.org/10.1001/jama.2010.1923)
292 [jama.2010.1923](https://doi.org/10.1001/jama.2010.1923).
- 293 **14.** Andrianopoulos, V. *et al.* Prognostic value of variables derived from the six-minute walk test in
294 patients with COPD: Results from the ECLIPSE study. *Respir. Medicine* **109**, 1138–1146 (2015),
295 <https://doi.org/10.1016/j.rmed.2015.06.013>.
- 296 **15.** Rochester, L. *et al.* A Roadmap to Inform Development, Validation and Approval of Digital Mobility
297 Outcomes: The Mobilise-D Approach. *Digit. Biomarkers* **4**, 13–27 (2020), [https://doi.org/10.1159/](https://doi.org/10.1159/000512513)
298 [000512513](https://doi.org/10.1159/000512513).
- 299 **16.** Annegarn, J. *et al.* Differences in Walking Pattern during 6-Min Walk Test between Patients with
300 COPD and Healthy Subjects. *PLoS ONE* **7**, e37329 (2012), [https://doi.org/10.1371/journal.pone.](https://doi.org/10.1371/journal.pone.0037329)
301 [0037329](https://doi.org/10.1371/journal.pone.0037329).
- 302 **17.** Galperin, I. *et al.* Associations between daily-living physical activity and laboratory-based assessments
303 of motor severity in patients with falls and Parkinson’s disease. *Park. & Relat. Disord.* **62**, 85–90
304 (2019), <https://doi.org/10.1016/j.parkreldis.2019.01.022>.
- 305 **18.** Espay, A. J. *et al.* Technology in Parkinson’s disease: Challenges and opportunities. *Mov. Disord.* **31**,
306 1272–1282 (2016), <https://doi.org/10.1002/mds.26642>.
- 307 **19.** Dobkin, B. H. & Dorsch, A. The Promise of mHealth. *Neurorehabilitation Neural Repair* **25**, 788–798
308 (2011), <https://doi.org/10.1177/1545968311425908>.
- 309 **20.** Weiss, A. *et al.* Toward Automated, At-Home Assessment of Mobility Among Patients With Parkinson
310 Disease, Using a Body-Worn Accelerometer. *Neurorehabilitation Neural Repair* **25**, 810–818 (2011),
311 <https://doi.org/10.1177/1545968311424869>.
- 312 **21.** Del Din, S., Godfrey, A., Mazzà, C., Lord, S. & Rochester, L. Free-living monitoring of Parkinson’s
313 disease: Lessons from the field. *Mov. Disord.* **31**, 1293–1313 (2016), [https://doi.org/10.1002/mds.](https://doi.org/10.1002/mds.26718)
314 [26718](https://doi.org/10.1002/mds.26718).
- 315 **22.** Hillel, I. *et al.* Is every-day walking in older adults more analogous to dual-task walking or to usual
316 walking? Elucidating the gaps between gait performance in the lab and during 24/7 monitoring. *Eur.*
317 *Rev. Aging Phys. Activity* **16**, 6 (2019), <https://doi.org/10.1186/s11556-019-0214-5>.
- 318 **23.** Del Din, S., Godfrey, A. & Rochester, L. Validation of an Accelerometer to Quantify a Comprehensive
319 Battery of Gait Characteristics in Healthy Older Adults and Parkinson’s Disease: Toward Clinical and

- 320 at Home Use. *IEEE J. Biomed. Heal. Informatics* **20**, 838–847 (2016), [https://doi.org/10.1109/JBHI.](https://doi.org/10.1109/JBHI.2015.2419317)
321 [2015.2419317](https://doi.org/10.1109/JBHI.2015.2419317).
- 322 **24.** Sosnoff, J. J., Goldman, M. D. & Motl, R. W. Real-life walking impairment in multiple sclerosis:
323 preliminary comparison of four methods for processing accelerometry data. *Multiple Scler. J.* **16**,
324 868–877 (2010), <https://doi.org/10.1177/1352458510373111>.
- 325 **25.** Pericleous, P. & Van Staa, T. P. The use of wearable technology to monitor physical activity in patients
326 with COPD: a literature review. *Int. J. Chronic Obstr. Pulm. Dis.* **Volume 14**, 1317–1322 (2019),
327 <https://doi.org/10.2147/COPD.S193037>.
- 328 **26.** Taraldsen, K. *et al.* The long-term effect of being treated in a geriatric ward compared to an
329 orthopaedic ward on six measures of free-living physical behavior 4 and 12 months after a hip
330 fracture - a randomised controlled trial. *BMC Geriatr.* **15**, 160 (2015), [https://doi.org/10.1186/](https://doi.org/10.1186/s12877-015-0153-6)
331 [s12877-015-0153-6](https://doi.org/10.1186/s12877-015-0153-6).
- 332 **27.** Boehme, P. *et al.* How soon will digital endpoints become a cornerstone for future drug development?
333 *Drug Discov. Today* **24**, 16–19 (2019), <https://doi.org/10.1016/j.drudis.2018.07.001>.
- 334 **28.** Del Din, S., Godfrey, A., Galna, B., Lord, S. & Rochester, L. Free-living gait characteristics in ageing
335 and Parkinson’s disease: impact of environment and ambulatory bout length. *J. NeuroEngineering*
336 *Rehabil.* **13**, 46 (2016), <https://doi.org/10.1186/s12984-016-0154-5>.
- 337 **29.** Khandelwal, S. & Wickstrom, N. Gait Event Detection in Real-World Environment for Long-Term
338 Applications: Incorporating Domain Knowledge Into Time-Frequency Analysis. *IEEE Transactions*
339 *on Neural Syst. Rehabil. Eng.* **24**, 1363–1372 (2016), <https://doi.org/10.1109/TNSRE.2016.2536278>.
- 340 **30.** Orendurff, M. S. How humans walk: Bout duration, steps per bout, and rest duration. *The J. Rehabil.*
341 *Res. Dev.* **45**, 1077–1090 (2008), <https://doi.org/10.1682/JRRD.2007.11.0197>.
- 342 **31.** Danks, K. A., Roos, M. A., McCoy, D. & Reisman, D. S. A step activity monitoring program
343 improves real world walking activity post stroke. *Disabil. Rehabil.* **36**, 2233–2236 (2014), <https://doi.org/10.3109/09638288.2014.903303>.
- 344 <https://doi.org/10.3109/09638288.2014.903303>.
- 345 **32.** Hickey, A., Del Din, S., Rochester, L. & Godfrey, A. Detecting free-living steps and walking
346 bouts: validating an algorithm for macro gait analysis. *Physiol. Meas.* **38**, N1–N15 (2017), <https://doi.org/10.1088/1361-6579/38/1/N1>.
- 347 <https://doi.org/10.1088/1361-6579/38/1/N1>.
- 348 **33.** Aminian, K., Najafi, B., Büla, C., Leyvraz, P.-F. & Robert, P. Spatio-temporal parameters of gait
349 measured by an ambulatory system using miniature gyroscopes. *J. Biomech.* **35**, 689–699 (2002),
350 [https://doi.org/10.1016/S0021-9290\(02\)00008-8](https://doi.org/10.1016/S0021-9290(02)00008-8).
- 351 **34.** El-Gohary, M. *et al.* Continuous Monitoring of Turning in Patients with Movement Disability. *Sensors*
352 **14**, 356–369 (2013), <https://doi.org/10.3390/s140100356>.

- 353 **35.** Haji Ghassemi, N. *et al.* Turning Analysis during Standardized Test Using On-Shoe Wearable Sensors
354 in Parkinson's Disease. *Sensors* **19**, 3103 (2019), <https://doi.org/10.3390/s19143103>.
- 355 **36.** Storm, F. A., Nair, K. P. S., Clarke, A. J., Van der Meulen, J. M. & Mazzà, C. Free-living and
356 laboratory gait characteristics in patients with multiple sclerosis. *PLOS ONE* **13**, e0196463 (2018),
357 <https://doi.org/10.1371/journal.pone.0196463>.
- 358 **37.** Gulley, E., Ayers, E. & Verghese, J. A comparison of turn and straight walking phases as predictors
359 of incident falls. *Gait & Posture* **79**, 239–243 (2020), <https://doi.org/10.1016/j.gaitpost.2020.05.002>.
- 360 **38.** Mariani, B., Jiménez, M. C., Vingerhoets, F. J. G. & Aminian, K. On-Shoe Wearable Sensors for Gait
361 and Turning Assessment of Patients With Parkinson's Disease. *IEEE Transactions on Biomed. Eng.*
362 **60**, 155–158 (2013), <https://doi.org/10.1109/TBME.2012.2227317>.
- 363 **39.** Jones, J. & Hunter, D. Qualitative Research: Consensus methods for medical and health services
364 research. *BMJ* **311**, 376–380 (1995), <https://doi.org/10.1136/bmj.311.7001.376>.
- 365 **40.** Perry, J. *Ganganalyse: Norm und Pathologie des Gehens* (Urban & Fischer, München [u.a.], 2003), 1
366 edn.
- 367 **41.** Whittle, M. W. *Gait analysis: An introduction* (Butterworth-Heinemann, Edinburgh, 2005), 3. edn.
- 368 **42.** Dijkstra, B., Kamsma, Y. P. & Zijlstra, W. Detection of Gait and Postures Using a Miniaturized Triaxial
369 Accelerometer-Based System: Accuracy in Patients With Mild to Moderate Parkinson's Disease. *Arch.*
370 *Phys. Medicine Rehabil.* **91**, 1272–1277 (2010), <https://doi.org/10.1016/j.apmr.2010.05.004>.
- 371 **43.** Iluz, T. *et al.* Automated detection of missteps during community ambulation in patients with Parkin-
372 son's disease: a new approach for quantifying fall risk in the community setting. *J. NeuroEngineering*
373 *Rehabil.* **11**, 48 (2014), <https://doi.org/10.1186/1743-0003-11-48>.
- 374 **44.** Hase, K. & Stein, R. B. Turning Strategies During Human Walking. *J. Neurophysiol.* **81**, 2914–2922
375 (1999), <https://doi.org/10.1152/jn.1999.81.6.2914>.
- 376 **45.** Perry, J. *Gait Analysis: Normal and Pathological Function* (SLACK, Thorofare, New Jersey, 1992),
377 1. edn.
- 378 **46.** Fritz, S. & Lusardi, M. White paper: "walking speed: the sixth vital sign". *J. Geriatr. Phys. Ther.* **32**,
379 46–9 (2009).
- 380 **47.** Gaßner, H. *et al.* Clinical Relevance of Standardized Mobile Gait Tests. Reliability Analysis Between
381 Gait Recordings at Hospital and Home in Parkinson's Disease: A Pilot Study. *J. Park. Dis.* **10**,
382 1763–1773 (2020), <https://doi.org/10.3233/JPD-202129>.
- 383 **48.** Warmerdam, E. *et al.* Long-term unsupervised mobility assessment in movement disorders. *The*
384 *Lancet Neurol.* **19**, 462–470 (2020), [https://doi.org/10.1016/S1474-4422\(19\)30397-7](https://doi.org/10.1016/S1474-4422(19)30397-7).
- 385 **49.** Vogel, C. *et al.* A Delphi study to build consensus on the definition and use of big data in obesity
386 research. *Int. J. Obes.* **43**, 2573–2586 (2019), <https://doi.org/10.1038/s41366-018-0313-9>.

- 387 **50.** Hsu, C. & Sandford, B. The Delphi Technique: Making Sense of Consensus. *Pract. Assessment, Res.*
388 *& Eval.* **12**, 1–8 (2007), <https://doi.org/10.7275/pdz9-th90>.
- 389 **51.** Murphy, M. *et al.* Consensus Development Methods, and their Use in Creating Clinical Guidelines.
390 *Heal. Technol. Assess.* **2**, 426–448 (1998), <https://doi.org/10.4135/9781848608344.n24>.
- 391 **52.** Boukdedid, R., Abdoul, H., Loustau, M., Sibony, O. & Alberti, C. Using and Reporting the Delphi
392 Method for Selecting Healthcare Quality Indicators: A Systematic Review. *PLoS ONE* **6**, e20476
393 (2011), <https://doi.org/10.1371/journal.pone.0020476>.
- 394 **53.** Diamond, I. R. *et al.* Defining consensus: A systematic review recommends methodologic criteria for
395 reporting of Delphi studies. *J. Clin. Epidemiol.* **67**, 401–409 (2014), [https://doi.org/10.1016/j.jclinepi.](https://doi.org/10.1016/j.jclinepi.2013.12.002)
396 [2013.12.002](https://doi.org/10.1016/j.jclinepi.2013.12.002).
- 397 **54.** R Core Team. R: A Language and Environment for Statistical Computing (2016).

398 **Acknowledgements**

399 The MOBILISE-D project has received funding from the Innovative Medicines Initiative 2 Joint Under-
400 taking under grant agreement No. 820820. This Joint Undertaking receives support from the European
401 Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical
402 Industries and Associations (EFPIA). BME gratefully acknowledges the support of the German Research
403 Foundation (DFG) within the framework of the Heisenberg professorship program (grant number ES
404 434/8-1). SDD and LR are supported by the National Institute for Health Research (NIHR) Newcastle
405 Biomedical Research Centre (BRC) based at Newcastle Upon Tyne Hospital NHS Foundation Trust and
406 Newcastle University. The work was also supported by the NIHR/Wellcome Trust Clinical Research
407 Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. CM is supported
408 by the National Institute for Health Research (NIHR) Sheffield Biomedical Research Centre (BRC) based
409 at Sheffield Teaching Hospital NHS Foundation Trust and University of Sheffield. All opinions are those
410 of the authors and not the funders.

411 **Author contributions**

412 All authors contributed to the conceptualization of the study, as well as to definitions and terminology. FK
413 conducted the study and analyzed the data. All authors wrote and/or edited the manuscript. All authors
414 approved of the final manuscript.

415 **Additional information**

416 **Competing interests**

417 The authors declare no competing interests.

418 **Data availability**

419 The datasets generated and analysed in the study are available in the Zenodo repository, <https://doi.org/10.5281/zenodo.4316564>.

421 **Code availability**

422 We used only free and open-source software. The code is available on <https://doi.org/10.5281/zenodo.4316739>.

424 Tables

Table 1. Identified domains and terms needing consensus.

Domain	Term	Aspect
<i>What</i> are you doing?	Walking	Physiological Relation to walking bouts
<i>Why</i> are you doing it?	Purposeful	Characteristics
<i>Where</i> are you doing it?	Real-world	Characteristics Standardized measurement Clinical environment
<i>How</i> are you doing it?	Walking bout	Characteristics
	Walking speed	Physical aspect Granularity Relation to walking bouts
	Turning	Characteristics

Table 2. Participant background assessed in the first round.

Professional background (n=64)	
Both technical and clinical background	25.0 %
Clinical background	40.6 %
Technical background	34.4 %
Expertise in gait analysis (n=66)	
None	12.1 %
0-5 years	50.0 %
5-10 years	12.1 %
10-15 years	7.6 %
15-20 years	4.6 %
> 20 years	13.6 %
Free-living expertise (n=65)	
No	35.4 %
Yes	64.6 %
Clinical expertise (n=62)	
Patients and healthy participants	71.0 %
Healthy participants	11.3 %
Patients	17.7 %

Table 3. Proportion of agreement and disagreement [%] of definitions. In round two, only those definitions were evaluated, which did not reach agreement in the first round. The lower limit of agreement was a priori defined as 75 %.

Term	Aspect	Disagreement	No opinion	Agreement	Consensus
Round one					
Walking	Physiological	6.1	3.0	90.9	yes
	Relation to walking bouts	0.0	3.0	97.0	yes
Purposeful	Characteristics	10.6	21.2	68.2	no
Real-world	Characteristics	4.6	1.5	93.9	yes
	Clinical environment	4.6	1.5	93.9	yes
	Standardized measurement	4.6	3.0	92.4	yes
Walking bout	Characteristics	15.1	6.1	78.8	yes
Walking speed	Physical definition	1.5	1.5	97.0	yes
	Granularity	1.5	6.1	92.4	yes
	Relation to walking bouts	15.2	24.2	60.6	no
Turning	Characteristics	3.0	3.0	94.0	yes
Round two					
Purposeful	Characteristics	15.7	5.9	78.4	yes
Walking bout	Characteristics	11.8	5.9	82.3	yes
Walking speed	Relation to walking bouts	15.7	7.8	76.5	yes

Table 4. Agreed definitions of terms related to real-world walking.

Term	Aspect	Definition
Walking	Physiological	<p>Human walking is a method of locomotion and is defined as initiating and maintaining a forward displacement of the centre of mass in an intended direction involving the use of the two legs, which provide both support and propulsion. The feet are repetitively and reciprocally lifted and set down whereby at least one foot is in contact with the ground at all times^{40,41}. Walking with walking aids is included in this definition.</p> <p>A step is the interval between the initial contacts of the ipsi- and contralateral foot⁴⁰ and corresponds to the forward displacement of the foot together with a forward displacement of the trunk⁴².</p> <p>A stride is the interval between two successive initial contacts of the same foot. As such, a stride is equivalent to the gait cycle and every stride contains two steps⁴⁰.</p>
	Relation to walking bouts	<p>Walking is made up of walking bouts and is equivalent to taking steps/stepping forward (thus stepping in place does not constitute walking) and is defined as starting from initial contact for the initial step until ending with full floor contact of the foot making the last step⁴².</p>
Purposeful	Characteristics	<p>Purposeful walking includes an intentional component of the movement (e.g. getting to the bathroom, catching the bus, going to the grocery store, going for a walk in the park, etc.).</p> <p>Purposeful walking may constitute certain characteristics (e.g. more constant walking velocity, lower variability of gait characteristics, straighter direction of locomotion than non-purposeful walking, specific context, etc.). Those gait characteristics are quantified based on discrete walking bouts.</p>

Real-world	Characteristics	<p>Real-world relates to the context in which walking takes place – that is free-living, unsupervised, uncontrolled and non-standardised. As such, it is unscripted as there are no instructions to the subject who does not need to interact with the wearable device(s).</p> <p>Real-world actions occur in non-simulated everyday situations in unconstrained environments with minimal consciousness of being tested. It is equivalent to actions at home or in the community over continuous periods of time²⁸.</p> <p>Synonymous terms are (environment of) daily living, or relating to daily-life. Home environment is used synonymously to real-world and daily-life without a separation of indoor and outdoor environment¹¹.</p> <p>Real-world is distinct from laboratory-based⁴³, supervised (= fully controlled and observed), and semi-controlled (walking ‘freely’ but with supervision) tests. It also is different from scripted/instructed walking, which can take place in the home or lab (such as walking tests like the 4x10m test, 6-minute walk test (6MWT) and timed up and go (TUG)).</p>
	Clinical environment	Free walking in hospitals is part of the real-world definition, but standardized supervised tests in a hospital are not. This excludes instructed actions, e.g. by medical professionals.
	Standardized measurement	Home-based tests, which are semi-standardized measurements performed in the home environment in a controlled or semi-controlled environment (such as short walk tests), are thus not regarded as being part of real-world . Home-based tests can nevertheless be an alternative to clinical tests and might be easier to conduct operationally and analyse than continuous monitoring (assuming standardized instructions).

Walking bout Characteristics A **walking bout (WB)** is a walking sequence containing at least two consecutive strides of both feet (e.g. *R-L-R-L-R-L* or *L-R-L-R-L-R*).

Start and end of a **walking bout** are determined by a resting period or any other activity (non-walking period). The initial step of a **WB** follows a non-walking period and the final step precedes the next non-walking period.

Walking speed Physical definition **Walking speed (WS)** is the distance covered by the whole body within a certain time interval / per unit time of walking. It is measured in meters per second and is the magnitude of the velocity vector (velocity includes direction and magnitude of walking)⁴¹.

Granularity **Walking speed** can be estimated at different granularities:

- Instantaneous WS varies from one instant to another during the walking cycle⁴¹
- Step-wise WS is the ratio between step distance (length) and step time²⁸
- Stride-wise WS³³
- Averaged over WBs
- Averaged over other time intervals (hourly, daily, weekly) based on multiple WBs

The granularity by which the WS is assessed should be related to clinical parameters for each population separately.

Relation to walking bouts **Walking speed** will be assessed with regard to walking bouts. Thus, the minimal length of one walking bout required to assess average walking speed is based on a sequence of 2 consecutive strides (e.g. *R-L-R-L-R-L* or *L-R-L-R-L-R*).

Turning

Characteristics The process of **turning** consists of decelerating the forward motion, rotating the body as a whole, and stepping out toward the new direction⁴⁴. Thus, **turning** includes a change of walking direction and change in angular orientation including a rotational movement of the body around the longitudinal axis. **Turning**, curvilinear walking, and straight walking involve different neuromotor strategies and need to be discriminated.

425 Figures




Figure 1. Five-point Likert scale for assessment of agreement.